DK1660054T3 - Ergolinholdigt middel til transdermal applikation - Google Patents

Ergolinholdigt middel til transdermal applikation

Info

Publication number
DK1660054T3
DK1660054T3 DK04735452T DK04735452T DK1660054T3 DK 1660054 T3 DK1660054 T3 DK 1660054T3 DK 04735452 T DK04735452 T DK 04735452T DK 04735452 T DK04735452 T DK 04735452T DK 1660054 T3 DK1660054 T3 DK 1660054T3
Authority
DK
Denmark
Prior art keywords
ergolin
ergoline
containing agent
transdermal application
tert
Prior art date
Application number
DK04735452T
Other languages
English (en)
Inventor
Reinhard Horowski
Johannes Tack
Katalin Tisa Bostedt
Dirk Schenk
Original Assignee
Axxonis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axxonis Pharma Ag filed Critical Axxonis Pharma Ag
Application granted granted Critical
Publication of DK1660054T3 publication Critical patent/DK1660054T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK04735452T 2003-09-03 2004-05-30 Ergolinholdigt middel til transdermal applikation DK1660054T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10341317A DE10341317B4 (de) 2003-09-03 2003-09-03 Transdermales therapeutisches System (TTS) zur Verabreichung von Ergolinverbindungen ausgenommen Pergolid
PCT/DE2004/001133 WO2005025546A1 (de) 2003-09-03 2004-05-30 Ergolinhaltiges mittel zur transdermalen applikation

Publications (1)

Publication Number Publication Date
DK1660054T3 true DK1660054T3 (da) 2008-11-17

Family

ID=34223453

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04735452T DK1660054T3 (da) 2003-09-03 2004-05-30 Ergolinholdigt middel til transdermal applikation

Country Status (15)

Country Link
US (1) US20070134309A1 (da)
EP (1) EP1660054B1 (da)
JP (1) JP2007504257A (da)
AT (1) ATE404183T1 (da)
AU (1) AU2004271679B2 (da)
CA (1) CA2504885A1 (da)
DE (2) DE10341317B4 (da)
DK (1) DK1660054T3 (da)
ES (1) ES2311825T3 (da)
HK (1) HK1086742A1 (da)
NZ (1) NZ546178A (da)
PL (1) PL1660054T3 (da)
PT (1) PT1660054E (da)
SI (1) SI1660054T1 (da)
WO (1) WO2005025546A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
JP5037831B2 (ja) * 2006-02-15 2012-10-03 久光製薬株式会社 凝集力向上及び徐放化の外用貼付剤
DE102006013307B3 (de) * 2006-03-21 2007-10-04 Ergonex Pharma Gmbh Tergurid/Protergurid zur Behandlung von chronischen Schmerzen
DE102006048130A1 (de) * 2006-10-06 2008-04-10 Axxonis Pharma Ag Transdermales therapeutisches System mit zweiphasigem Freisetzungsprofil

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797405A (en) * 1987-10-26 1989-01-10 Eli Lilly And Company Stabilized pergolide compositions
US5229129A (en) * 1989-07-12 1993-07-20 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5674875A (en) * 1993-05-04 1997-10-07 Eli Lilly And Company Method of blocking human 5-hydroxytryptamine-2 receptors
US6572879B1 (en) * 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
DE19626621A1 (de) * 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
US6623752B1 (en) * 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid
GB9711043D0 (en) * 1997-05-29 1997-07-23 Ciba Geigy Ag Organic compounds
DE19821788C1 (de) * 1998-05-15 1999-12-02 Sanol Arznei Schwarz Gmbh Transdermales Therapeutisches System (TTS) Pergolid enthaltend
DE10054713C2 (de) * 1999-11-29 2002-07-18 Lohmann Therapie Syst Lts Transdermale Therapeutische Systeme mit verbesserter Stabilität und ein Verfahren zu ihrer Herstellung
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
EP1385459A2 (en) * 2001-03-30 2004-02-04 Elan Pharmaceuticals, Inc. Transdermal delivery of pergolide
US20040120995A1 (en) * 2002-04-01 2004-06-24 Martin Debra A Transdermal delivery of pergolide

Also Published As

Publication number Publication date
AU2004271679A1 (en) 2005-03-24
DE10341317A1 (de) 2005-03-31
AU2004271679B2 (en) 2007-09-20
DE10341317B4 (de) 2008-10-23
PL1660054T3 (pl) 2009-01-30
HK1086742A1 (en) 2006-09-29
EP1660054A1 (de) 2006-05-31
SI1660054T1 (sl) 2008-12-31
CA2504885A1 (en) 2005-03-24
ES2311825T3 (es) 2009-02-16
JP2007504257A (ja) 2007-03-01
WO2005025546A1 (de) 2005-03-24
EP1660054B1 (de) 2008-08-13
ATE404183T1 (de) 2008-08-15
DE502004007855D1 (de) 2008-09-25
NZ546178A (en) 2008-12-24
US20070134309A1 (en) 2007-06-14
PT1660054E (pt) 2008-10-08

Similar Documents

Publication Publication Date Title
EA201000089A1 (ru) Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
DK1353668T3 (da) Fremgangsmåder til fremstillingen af farmaceutiske sammensætninger, der indeholder epothilonanaloger, til behandlingen af cancer
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
DK1337518T3 (da) Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
DK1615646T4 (da) Farmaceutiske formuleringer, der indeholder methylnaltrexon
CR11596A (es) Derivados de urea de tetrahidroquinoxalina, su preparacion y su aplicacion en terapeutica
DE60200194D1 (de) Freisetzungssystem von cyclopropenderivaten
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
ECSP10010533A (es) Derivados de 4-aminociclohexano sustituido
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
DK1311482T3 (da) Ikke-imidazolaryloxypiperidiner som H3-receptorligander
SG145715A1 (en) Mitoquinone derivatives used as mitochondrially targeted antioxidants
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
SV2002000249A (es) Derivados de tiazolilamida ref, lea 34082-sv
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação
NO20000832L (no) Fremgangsmåte for beskyttelse av undervannsinstallasjoner, samt anordning for gjennomföring av slik beskyttelse
DE60205870D1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
CY1105039T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ
CL2008001163A1 (es) Compuestos derivados de 1h-imidazo-4-il(piperazibn) metanona, inhibidores de renina superior, composicion farmaceutica que comprende a dichos compuestos; y uso de los compuestos para el tratamiento o prevencion de la hipertension.
CR9663A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
HK1086742A1 (en) Agent containing ergolin for transdermal application
NI201100034A (es) Uso de dronedarona para la preparación de un medicamento para la prevención de ictus o ataque isquémico transitorio.
NO20021409D0 (no) Hastighets-kontrollerte partikler